TherapeuticsMD (NYSE:TXMD) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of TherapeuticsMD (NYSE:TXMD – Get Rating) in a report released on Thursday morning. The brokerage issued a hold rating on the stock.

TherapeuticsMD Trading Up 0.9 %

Shares of TXMD stock opened at $3.48 on Thursday. TherapeuticsMD has a 52-week low of $1.99 and a 52-week high of $23.00.

TherapeuticsMD Company Profile

(Get Rating)

TherapeuticsMD, Inc operates as a pharmaceutical company. It focuses on the development and commercialization of products for women. The firm’s technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.